SaraladeviNaicker University of the Witwatersrand South Africa

SaraladeviNaicker
Saraladevi Naicker nMB ChB (Natal); MRCP (UK); PhD (Natal); FCP(PR-SA)nnProfessor Emeritus of Medicine; Academic Head, Department of Internal Medicine (2009-2013) and Division of Nephrology (2001-2014) and Graduate Studies (2014-2021) at the University of Witwatersrand Johannesburg. nnPresident of the SA Renal Society (1994-1997; 2012-2015); president of the SA Transplantation Society (1991-1993); chair of SA Ministerial Advisory Committee for Transplantation (2017-2019). Board member of African Association of Nephrology (2012-present), and South African Nephrology Society(2012-present).nnISN Committees: ISN Council (2005-2011) and ISN Executive Committee (2007-2009; 2019-2021); ISN Awards Committee (2019-2022). Chair of ISN Education Committee (2007-2008), ISN Educational Ambassadors Program (2009-2015); ISN Nominating Committee (2018-2019).nnShe has mentored and supervised a large number of postgraduate students in Internal Medicine and Nephrology clinically and at masters and doctoral level and was the recipient of the ISN Roscoe Robinson award (2009).
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Fatiu AbiolaArogundade Chairperson fatiu3@yahoo.comObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria Nigeria
FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comUniversidade Federal do Rio Grande do SulBrazil
OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduDuke University School of MedicineUnited States
  • Ethical Aspects of Race-based Genetic Testing
    AnaIltis Speaker iltisas@wfu.eduWake Forest UniversityUnited States
  • Contribution of ApoL1 Risk Genotype to HIVAN
    SaraladeviNaicker Speaker Saraladevi.Naicker@wits.ac.zaUniversity of the Witwatersrand South Africa
  • Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
    DwomoaAdu Speaker dwoms@blueyonder.co.ukUniversity of Ghana Medical SchoolGhana
  • Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
    OgoEgbuna Speaker ogo_egbuna@vrtx.comVertex Pharmaceuticals IncUnited States
  • Q and A
Hall C2